<DOC>
	<DOCNO>NCT02235298</DOCNO>
	<brief_summary>Dapagliflozin new emerge anti-diabetes medication . Dapagliflozin selective sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor , reduces hyperglycemia patient type 2 diabetes mellitus ( T2DM ) increase urinary glucose excretion , weight loss consistent associate finding . Because dapagliflozin increase urinary glucose excretion , weight loss could result reduce body fat secondary caloric loss fluid loss secondary osmotic diuresis combination factor . Nevertheless , whether Dapaglifozin may cause reduction visceral fat unknown . Hence , study investigator would like test hypothesis Dapaglifozin cause rapid significant reduction epicardial fat , visceral fat heart , type 2 diabetic patient . This hypothesis would test prospective interventional study 100 overweight obese type 2 diabetes subject .</brief_summary>
	<brief_title>Effects Dapagliflozin Epicardial Fat Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>• Type 2 diabetes , define ADA criterion HbA1c ≤ 8 % measure least 1 week prior study BMI ≥27 kg/m2 Pretreatment Metformin monotherapy Age &gt; 18 &lt; 70 year old • Known contraindication Farxiga , accordance risk safety information include late updated Prescribing Information Type 1 diabetes , define American Diabetes Association ( ADA ) criteria Insulin dependent treat type 2 diabetes Current use SGLT2 inhibitor , GLP 1 analog DPP4 inhibitor Glomerular Filtration Rate ( GFR ) &lt; 60 mL/min/1.73 m2 Patients poor glycemic control exclude maximize longterm patient retention without need History diabetes ketoacidosis Clinical sign symptoms New York Heart Association ( NYHA ) class IIIIV heart failure Clinical laboratory evidence chronic active liver disease Acute chronic infective disease Cancer chemotherapy Current use systemic corticosteroid 3 month prior study Known suspect allergy Dapaglifozin , excipients , relate product Pregnant , breastfeed intention become pregnant Females childbearing potential use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>epicardial fat</keyword>
	<keyword>diabetes</keyword>
	<keyword>dapagliflozin</keyword>
</DOC>